Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Traveller's diarrhoea vaccine transdermal - Valneva USA

Drug Profile

Traveller's diarrhoea vaccine transdermal - Valneva USA

Alternative Names: Escherichia coli vaccine transdermal - Valneva USA; ETEC vaccine - Valneva USA; Prophylactic TD vaccine patch; Transcutaneous ETEC vaccine - Valneva USA; Vaccine patch for traveller's diarrhoea - Valneva USA

Latest Information Update: 12 Dec 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Iomai Corporation
  • Developer Intercell USA
  • Class Adjuvants
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Escherichia coli infections; Traveller's diarrhoea

Most Recent Events

  • 11 Dec 2017 Intercell USA is now called Valneva USA
  • 13 Dec 2010 Discontinued - Phase-III for Escherichia coli infections in European Union (Transdermal)
  • 12 Dec 2010 Discontinued - Phase-II for Escherichia coli infections in India (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top